Friday 6 November 2026
Export BIO’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.8%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
382.51
13.51
+3.66%
Follow BIO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 7 | 5 | 6 |
| 10.84% | 2.50% | 3.11% | 14.27% | ||
| 7.62% | 1.75% | 2.17% | 9.99% | ||
ROIC |
0.41% | 0.55% | 0.49% | (0.54%) | |
Return on Tangible Assets |
25.94% | 6.61% | 8.63% | 39.11% | |
Average Days of Receivables |
65.08 | 60.07 | 62.28 | 59.49 | |
Free Cash Flow per Share |
13.74 | 13.26 | 13.20 | 12.29 | |
Free Cash Flow |
374.70 | 357.40 | 353.10 | 329.10 | |
Capital Expenditures |
(157.50) | (153.00) | (139.50) | (139.00) | |
| Other line items | |||||
Cash ROIC |
3.67% | 3.72% | 3.53% | 3.14% | |
Accounts Receivable Turnover |
5.66 | 6.09 | 5.68 | 5.84 | |
Accounts Payable Turnover |
9.89 | 9.20 | 8.81 | 9.64 | |
Inventory Turnover |
1.66 | 1.60 | 1.58 | 1.61 | |
Average Days of Payables |
37.87 | 38.97 | 42.05 | 38.56 | |
Days of Inventory on Hand |
217.45 | 225.60 | 228.76 | 226.42 | |
Tax Rate |
(0.24) | (0.24) | (0.37) | (0.23) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 10.29% | 10.20% | |
Selling, General and Administrative Expense of Revenue |
32.68% | 32.74% | 32.91% | 34.81% | |
Share Based Compensation of Revenue |
4.13% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.96 | 1.17 | 1.09 | (1.27) | |
Operating CF/Net income |
0.70 | 3.02 | 2.21 | 0.46 | |
Depreciation/Fixed assets |
0.56 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.52) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
94.75 | 96.07 | 96.81 | 96.81 | |
Operating CF per Share |
19.52 | 18.93 | 18.42 | 17.48 | |
Capex per Share |
(5.78) | (5.68) | (5.22) | (5.19) | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 6 Nov 2026